Brucine Dosing for ALS Treatment With Lower Toxicity Risk

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for amyotrophic lateral sclerosis (ALS) are limited by high costs and side effects, and traditional therapies like Nux vomica seed have narrow therapeutic windows and high toxicity, necessitating a safer and more effective alternative.

Innovation Solution

The application of brucine, an active component of Nux vomica seed, is explored for treating ALS, utilizing a dosage of 10 mg/kg to delay disease onset, prolong survival, and improve limb grip strength.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Nux vomica seed is used to treat ALS, then therapeutic effects are achieved through multi-pathway and multi-target mechanisms, but toxicity increases and therapeutic window narrows

Engineering Contradiction:

Improvetherapeutic effectVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the Nux vomica seed into its active component brucine, isolating the therapeutic element from the toxic whole. This segmentation allows for precise dosage control of brucine (0.03-0.6g/day) separate from the seed material, maintaining therapeutic effects while reducing toxicity by eliminating other seed components that contribute to harmful effects

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent extracts brucine from the Nux vomica seed through pharmacological research and isolation. This extraction process separates the beneficial active ingredient from the toxic matrix of the seed, enabling clinical use of pure brucine with controlled dosage (0.03-0.6g/day) that avoids the toxicity reactions occurring at higher doses of whole seed (＞0.9g)

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If approved drugs (Riluzole and Edaravone) are used for ALS treatment, then disease progression is delayed to some extent, but costs increase and side effects occur

Engineering Contradiction:

Improvedisease progression delayVSAvoidside effects and cost

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent positions brucine as a more accessible alternative to expensive approved drugs like Riluzole and Edaravone. Brucine, derived from traditional medicine resources, offers a lower-cost treatment option that can be administered at 0.03-0.6g/day, providing therapeutic benefits without the high financial burden and side effect profile of currently approved Western medications

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If Nux vomica seed dosage is increased to enhance therapeutic effect, then efficacy may improve, but toxicity reactions occur when dosage exceeds 0.9g

Engineering Contradiction:

Improvetherapeutic effectVSAvoidtoxicity reaction

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the dosage parameter from grams of whole Nux vomica seed to milligrams of isolated brucine. This parameter transformation allows for precise control at the molecular level, enabling effective doses (0.03-0.6g brucine/day) that remain below the toxic threshold (＞0.9g seed), thereby optimizing the efficacy-toxicity ratio through refined dosage measurement

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260021089A1Application method of brucine for treating amyotrophic lateral sclerosis

Publication Date: 2026.01.22 ZHEJIANG CHINESE MEDICAL UNIVERSITY

AI summary

An application method of brucine for treating amyotrophic lateral sclerosis (ALS) is provided, relating to the field of biomedicines. It can delay a time of onset of ALS, prolong survival time of ALS patients, delay a weakening of limb extension ability, and improve limb grip strength.